Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.3052W HIGH $219.71
Volume
242.75 K
Value Traded
325.98 M
Short % Float
16.51%
Days to Cover
3.8
-1.55%Week
-23.38%1 Month
+59.01%3 Month
+125.59%6 Month
-38.59%5 Year
+365.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.94 B
EPS (TTM)
-2.06
P/E Ratio
-
Ent. Value
8.51 B
Total Shares
62.71 M
Float Shares
64.01 M
Insiders
2.77%
Institutions
121.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TWST Catalyst Timeline
Dated clinical, regulatory and corporate events for Twist Bioscience Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Twist Bioscience Corporation
100Total events
2Upcoming
16Tier-1 (high impact)
2022 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Twist Bioscience joins Lilly TuneLab AI/ML drug discovery platform as antibody characterization data provider
▼Equity OfferingCorporate
Pricing of upsized $300.0 million public offering of 3,125,000 shares of common stock at $96.00 per share
▼Equity OfferingCorporate
Twist Bioscience commences $250.0M underwritten public offering of common stock
●Quarterly UpdateCorporate
Twist Bioscience reports fiscal 2026 third quarter financial results
◆Oral PresentationPresentation
Twist Bioscience presentation at William Blair 46th Annual Growth Stock Conference
▲Partnership / LicenseCorporate
Entered into bispecific licensing agreement with Invenra for B-Body platform
◆Oral PresentationPresentation
Twist Bioscience CEO and CFO to participate in fireside chats at upcoming investor conferences
▲Partnership / LicenseCorporate
Twist Bioscience enters licensing agreement with Invenra for B-Body bispecific antibody platform
▼Equity OfferingCorporate
Twist Bioscience acquires ~6% ownership stake in Invenra via preferred stock purchase
▲Product LaunchPost-Market
Launched Trinity Freestyle Fast Hybridization workflow for Element's AVITI sequencing platforms
▲Product LaunchPost-Market
Launched Twist Oncology DNA CGP Panel for genomic profiling
oncologysource ↗
◆Quarterly UpdateCorporate
Q4FY2025 revenue guidance ~$96M-$98M, gross margin 51%-52%, adjusted EBITDA $(6)M-$(8)M
▲Quarterly UpdateCorporate
Twist Bioscience reports fiscal Q3 2025 financial results with record revenue of $96.1M
▲Partnership / LicenseCorporate
Expanded collaboration with Element Biosciences for AVITI systems and Trinity flowcells
▲Product LaunchPost-Market
Launched humanized transgenic mouse model for antibody discovery services
▲Partnership / LicenseCorporate
Spin out of DNA Data Storage as Atlas Data Storage with $155M investment
▲Quarterly UpdateCorporate
Twist Bioscience reports fiscal Q1 2025 financial results with record revenue of $88.7M
▲Partnership / LicenseCorporate
Announced collaboration with Absci to design novel therapeutic using generative AI
▲Partnership / LicenseCorporate
Entered into royalty purchase agreement with XOMA Royalty Corporation for $15M cash
▲Timing GuidancePresentation
Expect to exit fiscal 2024 with adjusted EBITDA breakeven for core and biopharma businesses in Q4
●Quarterly UpdateCorporate
Twist Bioscience provides fiscal 2024 revenue guidance of $285M-$290M
▲Quarterly UpdateCorporate
Fiscal 2024 adjusted EBITDA breakeven for core business expected in Q4
▲First Patient DosedPBA-0405Trial
First patient dosed in Pure Biologics' Phase 0 study of PBA-0405
not specifiedsource ↗
Past FDA Catalysts and PDUFA Decisions
How TWST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TWST program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Laponis AdamOfficer (Chief Financial Officer) | Sell | -2,462 98,114 held | $156.30 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TWST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.4 % (-83.3 %) | 10.76 M | 104.63 K | -91.47% ( -1.12 M) |
TWST Institutional Ownership Trends
TWST Short Interest
Shares sold short, counted twice a month.
16.51%
Short % of Float
of tradable shares sold short
10.6M
Shares Sold Short
-15.5% vs prior count
3.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TWST ranks across every disease it competes in
Competitive Position is a premium feature
See how TWST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTWST News
TWST▲ +2.1%today
Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026
Twist Bioscience Corporation will release its fiscal 2026 fourth quarter and full year financial results on November 12, 2026. The results will cover the period ending September 30, 2026. A conference call is scheduled for 8:00 a.m. Eastern Time to discuss the results and provide updates.
Read more →TWSTTwist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Twist Bioscience Corporation has entered into a partnership with Lilly TuneLab, an AI/ML drug discovery platform developed by Eli Lilly. This collaboration will allow Twist to provide antibody characterization data services, including the AbLab model, to enhance the drug discovery process. The partnership aims to foster innovation in the biotech sector.
Read more →TWSTTwist Bioscience to Present at Baird 2026 Global Healthcare Conference
Twist Bioscience Corporation announced that its CEO, Dr. Emily M. Leproust, and CFO, Adam Laponis, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference. The event is scheduled for September 15, 2026, and will be webcast live, allowing broader access to the discussion.
Read more →TWST▲ +15.7%on this news
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Twist Bioscience Corporation has announced the pricing of an upsized public offering of 3,125,000 shares of common stock at $96.00 per share. The offering aims to raise $300 million in gross proceeds, which will be used for corporate purposes. All shares will be sold by Twist, indicating a strong demand for its stock.
Read more →TWST▲ +15.7%on this newsshared move
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist Bioscience Corporation has announced a proposed public offering of $250 million in common stock. The company also plans to grant underwriters a 30-day option to purchase an additional $37.5 million in shares. This move aims to bolster its financial resources and support future growth initiatives.
Read more →TWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation has announced the granting of 44,434 restricted stock units (RSUs) to 24 new employees as an inducement for their acceptance of employment. This move aligns with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting skilled professionals. The RSUs are part of the company's strategy to enhance its workforce.
Read more →TWST▲ +10.4%on this newsshared move
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
Twist Bioscience Corporation announced its financial results for the third quarter of fiscal 2026, which ended on June 30, 2026. The company highlighted its growth and value in the biotech industry. Investors can access detailed reports and presentations through their website.
Read more →TWSTTwist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
Twist Bioscience Corporation will release its financial results for the fiscal 2026 third quarter on August 3, 2026. The results will cover the period ending June 30, 2026, and will be announced before the market opens. Following the announcement, the company will host a conference call and live audio webcast to discuss the results and provide a business update.
Read more →TWSTTwist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
Twist Bioscience is scheduled to present at the William Blair 46th Annual Growth Stock Conference. Details regarding the presentation content or specific topics have not been disclosed in the article.
Read more →TWST▼ -7%on this news
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
Twist Bioscience has expanded its clonal genes offering to include long and complex sequences. This move aims to enhance their product portfolio and cater to a broader range of applications in synthetic biology. The expansion reflects the company's commitment to innovation and meeting customer needs in the biopharma sector.
Read more →TWST▼ -7%on this news
Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results
Twist Bioscience Corporation reported its fiscal second quarter 2026 financial results, showcasing a record revenue of $110.7 million, reflecting a 19% increase compared to the same quarter last year. This quarter marks the thirteenth consecutive quarter of growth for the company, with improved gross margins. Despite the positive financial results, the company reported a net loss of $44.0 million and an increase in selling, general and administrative expenses. Looking forward, Twist has raised its revenue guidance for fiscal 2026 and anticipates achieving adjusted EBITDA breakeven by the fourth quarter.
Read more →TWST▼ -7%on this news
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
Twist Bioscience has announced its financial results for the second quarter of fiscal 2026. The report includes key financial metrics and performance indicators, although specific details on revenue or growth were not disclosed in the provided text. The announcement is part of the company's ongoing financial reporting.
Read more →TWSTTwist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
Twist Bioscience Corporation will announce its fiscal 2026 second quarter financial results on May 4, 2026, before market opening. A conference call will follow at 8:00 a.m. ET for discussion and updates. Additionally, an Investor Day is scheduled for May 21, 2026, featuring a facility tour and presentations from senior leaders.
Read more →TWSTTwist Bioscience to Present at Upcoming Investor Conferences
Twist Bioscience Corporation announced that its CEO, Dr. Emily M. Leproust, and CFO, Adam Laponis, will participate in upcoming investor conferences through fireside chats. These events will be webcast live and available for replay for 30 days. The company emphasizes its role in supporting customers across various industries with its advanced DNA synthesis technology.
Read more →TWST▲ +7.7%on this newsshared move
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Twist Bioscience has entered a licensing agreement with Invenra to co-exclusively provide the B-Body bispecific antibody platform. This partnership aims to enhance Twist's antibody discovery services and meet the increasing demand for bispecific therapeutics. The deal includes a $5 million upfront payment and a 6% ownership stake in Invenra. Twist's CEO emphasizes the potential of bispecific antibodies in addressing unmet medical needs.
Read more →TWSTTwist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Twist Bioscience has launched two next-generation library preparation kits, the Twist TrueAmp and the Twist PCR-Free WGS Library Preparation Kits. These kits are designed to enhance sequencing accuracy and efficiency, particularly for low-input and difficult sample types. The TrueAmp polymerase and engineered ligase improve performance and reduce errors, catering to various clinical research applications.
Read more →TWSTTwist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - February 3, 2026
Twist Bioscience Corporation announced the grant of 114,869 equity awards to 52 new employees as an inducement for joining the company. This includes 107,742 restricted stock units (RSUs) and up to 7,127 performance stock units (PSUs). The awards are structured to vest over a 48-month period, contingent on continued employment and performance metrics.
Read more →TWST▲ +14%on this news
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
Twist Bioscience Corporation announced its financial results for the first quarter of fiscal 2026, ending December 31, 2025. The company highlighted its innovative DNA synthesis platform, which supports advancements in medicine, agriculture, and other sectors. A conference call is scheduled to discuss these results and company updates.
Read more →TWST▲ +14%on this newsshared move
Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results
Twist Bioscience reported financial results for the first quarter of fiscal 2026, showcasing record revenue of $103.7 million, a 17% increase from the same quarter last year. The company achieved a gross margin of 52.0%, marking an improvement over the previous year, and raised its full-year revenue guidance to between $435 million and $440 million. Despite these positives, the company posted a net loss of $30.5 million and continued to operate at a loss in adjusted EBITDA, though this figure improved from the prior year’s loss. Twist remains focused on maintaining revenue growth while aiming for profitability.
Read more →About Twist Bioscience Corporation
Headquarters681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next TWST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime